Barash Jed A, Whitledge James, Watson C James, Boyle Katherine, Lim Chun, Lev Michael H, DeMaria Alfred, Ganetsky Michael
Department of Medicine, Soldiers' Home, Chelsea, MA, USA.
Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
J Neurol Sci. 2020 Oct 15;417:117048. doi: 10.1016/j.jns.2020.117048. Epub 2020 Jul 17.
An opioid-associated amnestic syndrome (OAS) characterized by acute onset memory loss and bilateral hippocampal signal abnormalities on brain imaging in the setting of a history of opioid use, most notably fentanyl, has been reported. To date, however, there is no case definition to assist neurologists and other clinicians in identifying this syndrome. A multi-disciplinary collaboration of physicians, including neurologists, propose diagnostic criteria for OAS using cases that have been published in the medical literature or presented at conferences.
Cases were classified as confirmed, probable, or possible based on brain imaging findings and history or analytical testing supporting opioid use. Published articles and presentations were identified by discussion with public health authorities and a systematic search of PubMed. Included were articles, abstracts or posters through November 2019 that presented case reports or case series of a new-onset amnestic syndrome associated with bilateral hippocampal injury on imaging and/or prior opioid or other substance use. The percentages of cases that would meet confirmed, probable, or possible criteria were calculated.
Twenty-three publications from all sources met criteria for inclusion, accounting for 40 unique cases. Based on the case definition of OAS, 50% (20/40) were confirmed, 25% (10/40) were probable and 25% (10/40) were possible.
The development of a validated, formal case definition for OAS can assist neurologists and other clinicians in evaluating patients with amnesia and a history of opioid use.
据报道,一种与阿片类药物相关的遗忘综合征(OAS),其特征为急性起病的记忆丧失,且在有阿片类药物使用史(最显著的是芬太尼)的情况下,脑部成像显示双侧海马信号异常。然而,迄今为止,尚无病例定义可帮助神经科医生和其他临床医生识别该综合征。包括神经科医生在内的多学科医生合作团队,利用已发表在医学文献或会议上展示的病例,提出了OAS的诊断标准。
根据脑部成像结果以及支持阿片类药物使用的病史或分析检测结果,将病例分为确诊、疑似或可能病例。通过与公共卫生当局讨论并系统检索PubMed来确定已发表的文章和报告。纳入的内容包括截至2019年11月发表的文章、摘要或海报,这些文献展示了与影像学上双侧海马损伤及既往阿片类药物或其他物质使用相关的新发遗忘综合征的病例报告或病例系列。计算符合确诊、疑似或可能标准的病例百分比。
来自所有来源的23篇出版物符合纳入标准,共计40例独特病例。根据OAS的病例定义,50%(20/40)为确诊病例,25%(10/40)为疑似病例,25%(10/40)为可能病例。
制定经过验证的OAS正式病例定义,可帮助神经科医生和其他临床医生评估有失忆症且有阿片类药物使用史的患者。